Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Pharmacy staff profile

Dr Hesh Al-Sallami

PositionSenior Lecturer, Pharmacy Programmes Admissions Co-ordinator
QualificationsBPharm MClinPharm PhD
Research summaryClinical practice, clinical pharmacology, clinical education
TeachingClinical Pharmacy practice and clinical pharmacology
Memberships
  • Registered Pharmacist, RegPharmNZ
  • Member of the Population Approach Group in Australia and New Zealand
  • Member of the Australasian Society for Clinical and Experimental Pharmacologists
  • Member of the Pharmaceutical Society of New Zealand
  • Secretary of the Otago branch of the Pharmaceutical Society of New Zealand committee
  • Member of the New Zealand Hospital Pharmacists’ Association
ClinicalLocum pharmacists, community and hospital pharmacy

Research

My area of research is Clinical Pharmacy Practice with a focus on the individualisation of pharmacotherapy in order to optimise patient clinical outcomes. My research focus is drug dosing in relation to body composition in children and in obese individuals. The clinical application of my research has been in the areas of anticoagulation and in insulin dosing in diabetes. My research interests also include clinical pharmacy education and pharmacists’ professional competency.

Publications

Mooranian, A., Wagle, S. R., Kovacevic, B., Takechi, R., Mamo, J., Lam, V., … Al-Sallami, H., & Al-Salami, H. (2020). Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 10, 106. doi: 10.1038/s41598-019-53999-1

Majid, A., Blackwell, M., Broadbent, R. S., Barker, D. P., Al-Sallami, H. S., Edmonds, L., Kerruish, N., & Wheeler, B. J. (2019). Newborn vitamin K prophylaxis: A historical perspective to understand modern barriers to uptake. Hospital Pediatrics, 9(1), 55-60. doi: 10.1542/hpeds.2018-0104

Sinha, J., Duffull, S. B., Green, B., & Al-Sallami, H. S. (2019). Evaluating the relationship between lean liver volume and fat-free mass. Clinical Pharmacokinetics. Advance online publication. doi: 10.1007/s40262-019-00824-7

Sinha, J., Al-Sallami, H. S., & Duffull, S. B. (2019). Choosing the allometric exponent in covariate model building. Clinical Pharmacokinetics, 28(1), 89-100. doi: 10.1007/s40262-018-0667-0

Mooranian, A., Zamani, N., Luna, G., Al-Sallami, H., Mikov, M., Goločorbin-Kon, S., … Al-Salami, H. (2019). Bile acid-polymer-probucol microparticles: Protective effect on pancreatic β-cells and decrease in Type 1 diabetes development in a murine mode. Pharmaceutical Development & Technology. Advance online publication. doi: 10.1080/10837450.2019.1665069

Journal - Research Article

Mooranian, A., Wagle, S. R., Kovacevic, B., Takechi, R., Mamo, J., Lam, V., … Al-Sallami, H., & Al-Salami, H. (2020). Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 10, 106. doi: 10.1038/s41598-019-53999-1

Majid, A., Blackwell, M., Broadbent, R. S., Barker, D. P., Al-Sallami, H. S., Edmonds, L., Kerruish, N., & Wheeler, B. J. (2019). Newborn vitamin K prophylaxis: A historical perspective to understand modern barriers to uptake. Hospital Pediatrics, 9(1), 55-60. doi: 10.1542/hpeds.2018-0104

Mooranian, A., Zamani, N., Luna, G., Al-Sallami, H., Mikov, M., Goločorbin-Kon, S., … Al-Salami, H. (2019). Bile acid-polymer-probucol microparticles: Protective effect on pancreatic β-cells and decrease in Type 1 diabetes development in a murine mode. Pharmaceutical Development & Technology. Advance online publication. doi: 10.1080/10837450.2019.1665069

Sinha, J., Al-Sallami, H. S., & Duffull, S. B. (2019). Choosing the allometric exponent in covariate model building. Clinical Pharmacokinetics, 28(1), 89-100. doi: 10.1007/s40262-018-0667-0

Sinha, J., Duffull, S. B., Green, B., & Al-Sallami, H. S. (2019). Evaluating the relationship between lean liver volume and fat-free mass. Clinical Pharmacokinetics. Advance online publication. doi: 10.1007/s40262-019-00824-7

Abdul Aziz, Y. H., Al-Sallami, H. S., Wiltshire, E., Rayns, J., Willis, J., McClintock, J., Medlicott, N., Wheeler, B. J., the Paediatric Society of New Zealand Diabetes Clinical Network. (2019). Insulin pump initiation and education for children and adolescents: A qualitative study of current practice in New Zealand. Journal of Diabetes & Metabolic Disorders. Advance online publication. doi: 10.1007/s40200-019-00390-6

Dowd, L. A., Wheeler, B. J., Al-Sallami, H. S., Broadbent, R. S., Edmonds, L. K., & Medlicott, N. J. (2019). Paracetamol treatment for patent ductus arteriosus: Practice and attitudes in Australia and New Zealand. Journal of Maternal-Fetal & Neonatal Medicine, 32(18), 3039-3044. doi: 10.1080/14767058.2018.1456520

Al-Sallami, H., & Loke, S.-K. (2018). Learning a complex dose–response relationship with the computer simulation CoaguSim. Currents in Pharmacy Teaching & Learning. Advance online publication. doi: 10.1016/j.cptl.2018.07.009

Muller, M., Wheeler, B. J., Blackwell, M., Colas, M., Reith, D. M., Medlicott, N. J., & Al-Sallami, H. S. (2018). The influence of patient variables on insulin total daily dose in paediatric inpatients with new onset type 1 diabetes mellitus. Journal of Diabetes & Metabolic Disorders. Advance online publication. doi: 10.1007/s40200-018-0355-5

Mooranian, A., Negrulj, R., Takechi, R., Mamo, J., Al-Sallami, H., & Al-Salami, H. (2018). The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: Potential hypoglycaemic and anti-inflammatory effects. Drug Delivery & Translational Research, 8(3), 543-551. doi: 10.1007/s13346-017-0473-5

Mooranian, A., Zamani, N., Takechi, R., Al-Sallami, H., Mikov, M., Goločorbin-Kon, S., … Al-Salami, H. (2018). Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artificial Cells, Nanomedicine, & Biotechnology. Advance online publication. doi: 10.1080/21691401.2018.1511572

Gogoi-Tiwari, J., Williams, V., Waryah, C. B., Costantino, P., Al-Salami, H., Mathavan, S., … Al-Sallami, H., & Mukkur, T. (2017). Mammary gland pathology subsequent to acute infection with strong versus weak biofilm forming Staphylococcus aureus bovine mastitis isolates: A pilot study using non-invasive mouse mastitis model. PLoS ONE, 12(1), e0170668. doi: 10.1371/journal.pone.0170668

Selvakumar, D., Al-Sallami, H. S., de Bock, M., Ambler, G. R., Benitez-Aguirre, P., Wiltshire, E., … Willis, J., Wheeler, B. J., on behalf of the Paediatric Society of New Zealand Diabetes Clinical Network. (2017). Insulin regimens for newly diagnosed children with type 1 diabetes mellitus in Australia and New Zealand: A survey of current practice. Journal of Paediatrics & Child Health, 53(12), 1208-1214. doi: 10.1111/jpc.13631

Al-Sallami, H., Newall, F., Monagle, P., Ignjatovic, V., Cranswick, N., & Duffull, S. (2016). Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients. British Journal of Clinical Pharmacology, 82(1), 178-184. doi: 10.1111/bcp.12930

Tordoff, J. M., Ailabouni, N. J., Browne, D. P., Al-Sallami, H. S., & Gray, A. R. (2016). Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand. International Journal of Clinical Pharmacy, 38(4), 941-949. doi: 10.1007/s11096-016-0318-1

Negrulj, R., Mooranian, A., Chen-Tan, N., Al-Sallami, H. S., Mikov, M., Golocorbin-Kon, S., … Al-Salami, H. (2016). Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artificial Cells, Nanomedicine, & Biotechnology, 44(5), 1290-1297. doi: 10.3109/21691401.2015.1024845

Al-Sallami, H. S., & Medlicott, N. J. (2015). Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma. Journal of Pharmacy & Pharmacology, 67(2), 209-214. doi: 10.1111/jphp.12333

Mooranian, A., Negrulj, R., Al-Sallami, H. S., Fang, Z., Mikov, M., Golocorbin-Kon, S., … Al-Salami, H. (2015). Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech, 16(1), 45-52. doi: 10.1208/s12249-014-0205-9

Mooranian, A., Negrulj, R., Al-Sallami, H. S., Fang, Z., Mikov, M., Golocorbin-Kon, S., … Al-Salami, H. (2015). Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. Journal of Microencapsulation, 32(2), 151-156. doi: 10.3109/02652048.2014.958204

Al-Sallami, H. S., Goulding, A., Grant, A., Taylor, R., Holford, N., & Duffull, S. B. (2015). Prediction of fat-free mass in children. Clinical Pharmacokinetics, 54(11), 1169-1178. doi: 10.1007/s40262-015-0277-z

Mooranian, A., Negrulj, R., Chen-Tan, N., Al-Sallami, H. S., Fang, Z., Mukkur, T. K., Mikov, M., … Al-Salami, H. (2014). Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Design, Development & Therapy, 8, 1221-1230. doi: 10.2147/dddt.s67349

Mooranian, A., Negrulj, R., Chen-Tan, N., Al-Sallami, H. S., Fang, Z., Mukkur, T., Mikov, M., … Al-Salami, H. (2014). Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A characterization study. Drug Design, Development & Therapy, 8, 1003-1012. doi: 10.2147/dddt.s65396

Loke, S.-K., Al-Sallami, H. S., Wright, D. F. B., McDonald, J., Jadhav, S., & Duffull, S. B. (2012). Challenges in integrating a complex systems computer simulation in class: An educational design research. Australasian Journal of Educational Technology, 28(4), 671-683. doi: 10.14742/ajet.834

Wright, D. F. B., Pavan Kumar, V. V., Al-Sallami, H. S., & Duffull, S. B. (2011). The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: Simulations from a pharmacokinetic—pharmacodynamic model. Basic & Clinical Pharmacology & Toxicology, 109(6), 494-498. doi: 10.1111/j.1742-7843.2011.00757.x

Wright, D. F. B., Al-Sallami, H. S., Jackson, P. M., & Reith, D. M. (2010). Falsely elevated vancomycin plasma concentrations sampled from central venous implantable catheters (portacaths). British Journal of Clinical Pharmacology, 70(5), 769-772. doi: 10.1111/j.1365-2125.2010.03749.x

Al-Sallami, H. S., Barras, M. A., Green, B., & Duffull, S. B. (2010). Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clinical Pharmacokinetics, 49(9), 567-571. doi: 10.2165/11532960-000000000-00000

Al-Sallami, H. S., Kumar, V. V. P., Landersdorfer, C. B., Bulitta, J. B., & Duffull, S. B. (2009). The time course of drug effects. Pharmaceutical Statistics, 8, 176-185. doi: 10.1002/pst.393

Al-Sallami, H., Ferguson, R., Wilkins, G., Gray, A., & Medlicott, N. J. (2008). Bleeding events in patients receiving enoxaparin for the management of non-ST-elevation acute coronary syndrome (NSTEACS) at Dunedin Public Hospital, New Zealand. New Zealand Medical Journal, 121(1285). Retrieved from http://journal.nzma.org.nz/journal/121-1285/3342/content.pdf

Al-Sallami, H., Ball, P. A., & Davey, A. (2001). Metered-dose inhaler with spacer versus nebuliser for acute exacerbation of asthma - a literature review. Australian Journal of Hospital Pharmacy, 31(3), 189-192.

^ Top of page

Journal - Research Other

Hennig, S., Hannam, J. A., Kirkpatrick, C. M. J., Staatz, C. E., Holford, S., Duffull, S. B., Al-Sallami, H. S., … Foster, D. J. R. (2019). Pharmacometrics in Australasia: Twenty years of Population Approach Group of Australia and New Zealand. CPT: Pharmacometrics & Systems Pharmacology, 8(10), 701-704. doi: 10.1002/psp4.12460

Mooranian, A., Zamani, N., Takechi, R., Al-Sallami, H., Mikov, M., Goločorbin-Kon, S., … Al-Salami, H. (2019). Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Therapeutic Delivery, 10(9), 563-571. doi: 10.4155/tde-2019-0052

Reith, D. M., & Al-Sallami, H. S. (2018). Comment on van Rongen et al., "Higher midazolam clearance in obese adolescents compared with morbidly obese adults". Clinical Pharmacokinetics. Advance online publication. doi: 10.1007/s40262-018-0691-0

Sinha, J., Duffull, S. B., & Al-Sallami, H. S. (2018). A review of the methods and associated mathematical models used in the measurement of fat-free mass. Clinical Pharmacokinetics, 57(7), 781-795. doi: 10.1007/s40262-017-0622-5

Al-Sallami, H. S., Cheah, S. L., Han, S. Y., Liew, J., Lim, J., Ng, M. A., Solanki, H., Soo, R. J., Tan, V., & Duffull, S. B. (2014). Between-subject variability: Should high be the new normal? European Journal of Clinical Pharmacology, 70(11), 1403-1404. doi: 10.1007/s00228-014-1740-8

Wright, D. F. B., Al-Sallami, H. S., & Duffull, S. B. (2013). Is the dose of dabigatran really more predictable than warfarin? British Journal of Clinical Pharmacology, 76(6), 997-998. doi: 10.1111/bcp.12144

Duffull, S. B., Wright, D. F. B., Al-Sallami, H. S., Zufferey, P. J., & Faed, J. M. (2012). Dabigatran: Rational dose individualisation and monitoring guidance is needed. New Zealand Medical Journal, 125(1357). Retrieved from http://www.nzma.org.nz/journal

Al-Sallami, H., Jordan, S., Ferguson, R., Medlicott, N. J., Schollum, J., & Duffull, S. B. (2010). Current enoxaparin dosing guidelines have dubious credibility [Viewpoint]. New Zealand Medical Journal, 123(1313). Retrieved from http://journal.nzma.org.nz/journal/123-1313/4076/content.pdf

More publications...